153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)JC Goh, Michael Millward, Amy Body et al.|Annals of Oncology|2021Cited by 3
156P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase Ib studyC. Cui, Jun Guo, Matteo S. Carlino et al.|Annals of Oncology|2021Cited by 1